David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma. Website:
Twitter:
Facebook:
LinkedIn:
Dr. McDermott on the Use of Anti–PD-1 Combinations in mRCC
David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma. Website:
Twitter:
Facebook:
LinkedIn:
![You Can Work Better Even With Depression-Dr. Deepak Kelkar [MD] Psychiatrist Hypnotherapist](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vNm0F5Bj-vkBuYrAowlu3WTQSjF6xuLx6_BjqeRW7dNbXcxAkj9cXBe3CW54FE81a2lHu5mXcBNh4zdr9zgFlQoubdiudvuZpNAkB16CldVKX6Ag=w680)
0 Comments